ArticleNPJ precision oncology2026

SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

Jialin Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.